Sort by
Refine Your Search
-
with fewer immediate and long-term side effects of treatment. https://www.icr.ac.uk/research-and-discoveries/icr-divisions/radiotherapy-and-imaging/stromal-radiobiology What we offer A dynamic and
-
collaboratively provide exceptional patient care while driving scientific discoveries that shape the future of cancer treatment. This research laboratory investigates how radiotherapy interacts with the tumor
-
: This position will contribute to the academic mission of the department in clinical service, research, and education. The person hired will aid in clinical implementation of advanced radiotherapy
-
of the lead radiation physicist assigned to them and develop competency in all areas of radiotherapy clinical coverage. Reviews OSU radiation treatment charts, initiates and supports departmental developmental
-
university professor, significant scientific and professional achievements, specialisation in clinical oncology and specialisation in oncological radiotherapy meeting the requirements set out in Art. 113
-
– there are excellent nurseries, pre-schools, private and public schools in the area Apply now if you are: Specialised in Oncology (radiotherapy equivalent to the Danish klinisk onkologi), with a minimum of 1 year of
-
prospective clinical data. Specifically, the research activities include: 1. analysis of the state of the art in radiotherapy treatments for cancer 2. study and development of microstructural simulation
-
consequently, resistance to standard drugs such as cisplatin and radiotherapy. This project will 1. Assess levels of this protein in biobanked bladder cancer tissue samples and correlate with stored patient data
-
, and emerging modalities such as FLASH radiotherapy. Positive factors for consideration include, but are not limited to, candidates who bring a strong, independent research program with expertise in
-
oncology, especially in the field of High-Precision Radiotherapy Profound clinical qualification in in the field of radiation oncology Successful and continuous acquisition of competitive third-party funds